Background and Purpose-Five randomized controlled trials have consistently shown that mechanical thrombectomy (MT) in addition to best medical treatment (±intravenous tissue-type plasminogen activator) improves outcome after acute ischemic stroke in patients with large artery anterior circulation stroke. Whether direct MT is equally effective as combined intravenous thrombolysis with MT (ie, bridging thrombolysis) remains unclear. Methods-We retrospectively compared clinical and radiological outcomes in 167 bridging patients with 255 patients receiving direct MT because of large artery anterior circulation stroke. We matched all patients from the direct MT group who would have qualified for intravenous tissue-type plasminogen activator with controls from the bridging group, using multivariate and propensity score analyses. Functional independence was defined as modified Rankin Scale score of 0 to 2. Results-From February 2009 to August 2014, 40 patients from the direct MT group would have qualified for bridging thrombolysis but were treated with MT only. Clinical and radiological characteristics did not differ from the bridging cohort, except for higher rates of hypercholesterolemia (P=0.019), coronary heart disease (P=0.039), and shorter intervals from symptom onset to endovascular intervention (P=0.01) in the direct MT group. Functional independence, mortality, and intracerebral hemorrhage rates did not differ (P>0.1). After multivariate matching analysis outcome in both groups did not differ, except for lower rates of asymptomatic intracerebral hemorrhage (P=0.023) and lower mortality (P=0.007) in the direct MT group. Conclusions-In patients with large anterior circulation stroke, direct mechanical intervention seems to be equally effective as bridging thrombolysis. A randomized trial comparing direct MT with bridging therapy is warranted. (Stroke.
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ntravenous thrombolysis with recombinant tissue-type plasminogen activator (intravenous tPA) has been the only approved therapy for acute ischemic stroke for almost 20 years. 1 Recently, a new era in acute stroke treatment has begun: 5 randomized controlled trials have consistently shown that endovascular clot retrieval in addition to best medical treatment (±intravenous tPA) improves outcome in acute anterior circulation stroke patients with proximal vessel occlusion. [2] [3] [4] [5] [6] The main reason for the difference in outcome was mechanical thrombectomy (MT) because rates of patients receiving intravenous tPA did not differ in both groups. 7 Whether treatment with intravenous tPA before MT (ie, bridging therapy) is still necessary has now become a matter of debate.
Administration of intravenous tPA before MT has several potential benefits: intravenous tPA can be started earlier than MT, intravenous tPA might contribute to higher recanalization rates, and intravenous tPA may help recanalize thrombi in small vessels and in the microvascular structure, inaccessible
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for endovascular devices. 7 On the contrary, intravenous tPA has potential side effects and limitations: it may increase the risk of intracerebral hemorrhage (ICH) and systemic bleeding complications; recanalization rates after intravenous tPA in large-vessel occlusions and in patients with large thrombi are poor 8 ; the therapeutic window for intravenous tPA is narrow; administration of antiplatelets and heparin is limited after intravenous tPA; intravenous tPA has an impact on healthcare costs; a substantial number of patients have contraindications for intravenous tPA; and finally in some patients administration of intravenous tPA might delay endovascular therapy (EVT).
The aim of the present retrospective investigation was to compare effectiveness (clinical outcomes, reperfusion rates) and safety (bleeding complications) of immediate and direct MT alone versus bridging thrombolysis.
Patients and Methods
Our study is based on the Bernese stroke registry, a prospective data collection of patients with acute ischemic stroke. From February 2009 to August 2014, 1222 patients with stroke were treated with intravenous-and intra-arterial thrombolysis at our stroke center. For our retrospective analysis, we selected all patients who were treated with endovascular thrombolysis (n=738), of which 480 received direct endovascular intervention and 258 bridging thrombolysis. We excluded all patients who received endovascular pharmacological treatment (bridging group: 73; MT group: 204 patients), patients with posterior circulation strokes (bridging group: 18; MT group: 21 patients), and patients lost for follow-up (bridging group: 11; MT group: 16 patients). One hundred and fifty-six patients were treated with bridging thrombolysis and 239 with direct MT. Forty of 239 patients from the direct MT group would have qualified for bridging thrombolysis and 199 not. The contraindications against intravenous tPA of those 199 patients are given in Figure 1 .
Baseline characteristics such as demographic data, vascular risk factors, laboratory findings, treatment modality, and time from symptom onset to diagnosis and treatment were recorded for all patients. Stroke severity was assessed by a stroke neurologist using the National Institute of Health Stroke Scale (NIHSS) score. 9 Immediately after clinical evaluation, all patients underwent computed tomographic (CT) or magnetic resonance (MR) imaging to rule out intracranial hemorrhage and CT angiography or MR angiography to assess the site of vessel occlusion. The general approach to perform thrombolysis at our center has been described previously. [10] [11] [12] Intravenous thrombolysis in our institution was performed according to international and institutional guidelines. 13, 14 Our bridging group received either full dose (0.9 mL/kg body weight) or two-thirds dose (0.6 mL/kg body weight) intravenous tPA within 4.5 hours after symptom onset. Intravenous tPA was usually started in the scanner immediately after exclusion of ICH. Patients with proximal vessel occlusions in the anterior circulation, defined as occlusions of the internal carotid artery and of the main stem of the middle cerebral artery including M1 and 12 However, final decision on the treatment approach was individualized on a case-bycase basis at the discretion of the interdisciplinary team of neurologists and neuroradiologists. Therefore, in some situations -especially in case of large vessel occlusion with a suspicion of a large thrombus burden -the team sometimes decided against bridging thrombolysis and performed direct MT. The number of senior stroke neurologists and interventional neuroradiologists involved in decision making during the study period as well as the current version of the Bernese thrombolysis guidelines are listed in Tables I and II in the online-only Data Supplement. Digital subtraction angiography was performed via transfemoral approach using a biplane, high-resolution angiography system. In general, a 4-vessel cerebral angiography was performed before the intervention. Endovascular recanalization procedures consisted of a combination of several approaches depending on occlusion pattern and operator preference: mechanical recanalization using thrombaspiration and stent retrievers and placement of extracranial stents. The interventional neuroradiologists decided together with the stroke neurologist on the use of urokinase, MT, and-if necessarystenting of the extracranial internal carotid artery. Twenty-four hours after treatment, or in any case of clinical deterioration, a CT or an MR imaging scan was performed. Symptomatic ICH (sICH) and asymptomatic ICH were classified according to the PROACT II (Prolyse in Acute Cerebral Thrombembolism II) study protocol. 15 Furthermore, any systemic bleeding was documented, but local hematoma at the catheter incision site was not considered as systemic bleeding. Recanalization rates were assessed immediately after angiography using thrombolysis in myocardial infarction (TIMI) 16 classification, reperfusion with the thrombolysis in cerebral infarction (TICI) classification. 17 Furthermore, status of vessel recanalization was assessed in patients who underwent CT or MR angiography after 24 hours. Stroke pathogenesis was classified according to Trial of ORG 10172 in Acute Stroke Treatment (TOAST) criteria. 18 Clinical outcome was prospectively assessed 3 months after the stroke using the modified Rankin Scale (mRS), the primary outcome variable of our analysis. 19 Furthermore, all patients were invited for a 3-month outpatient visit, and clinical examination included the NIHSS scale. The study was performed according to the ethical guidelines of the Canton of Bern and with corresponding permission.
Statistical Analysis
We compared background characteristics, treatment data, and outcomes between bridging patients and 40 patients treated with direct MT who would have qualified for bridging therapy. Differences between the 2 groups were assessed using Fisher's exact test for categorical variables and the Wilcoxon rank-sum test for continuous variables. Complete recanalization was defined as TIMI-3, complete reperfusion as TICI 2b-3. Functional independence was defined as an mRS score of 0 to 2 and excellent clinical outcome, as an mRS score of 0 to 1. In our primary analysis, we performed a 1:1 matchedpairs analysis and compared patients from the direct MT group with matched patients from the bridging group using McNemar's test (categorical variables) and the Wilcoxon signed-rank test (continuous variables); 1:1 matching was performed using a multivariate genetic algorithm 20 taking the following baseline variables into account: age, NIHSS, time from symptom onset to diagnosis, hypertension, and thrombus location (internal carotid artery or middle cerebral artery), and we also performed supportive analyses based on 1:2 matching. Furthermore, supportive analyses used the propensity score, computed based on a multiple logistic regression model accounting for additional explanatory variables (see Table III in the online-only Data Supplement for details). The propensity score was used to create alternative matched pairs as well as a covariate in multiple linear and logistic regression models of the outcomes evaluating the effect of the treatment choice. Two-sided P values <0.05 were considered statistically significant. Analyses were performed using R (version 3.1.2 -R Core Team [2014] ; R: A language and environment for statistical computing; R Foundation for Statistical Computing, Vienna, Austria).
Results
Baseline characteristics of 40 patients from the MT group without contraindications for intravenous tPA and 156 patients treated with bridging thrombolysis are shown in Table 1 . There was a trend toward a better improvement on the NIHSS score from baseline to the 3-month follow-up in the direct MT group than in bridging patients (P=0.049). Recanalization and reperfusion rates at the end of the intervention did not differ (TIMI-3: P=0.70; TICI 2b-3: P=0.37), but patients in the MT group had higher recanalization rates 24 hours after intervention (P=0.043). Subgroup analyses of patients with internal carotid artery occlusions showed similar outcome results (see Table IV in the online-only Data Supplement).
Matched-Pairs Analysis and Supportive Models
A total of 40 MT patients were evaluable for the matchedpairs analysis with the multivariate method. Results are shown in Table 2 : baseline variables such as age, NIHSS, sex, and site of vessel occlusion were equally distributed in both groups. Recanalization and reperfusion rates as well as sICH and systemic bleeding complications did not differ between groups in multivariate matching analyses, but rates of asymptomatic ICH were significantly higher in the bridging cohort than in patients after MT in the matched-pairs analysis (P=0.023). Functional independence measured with the mRS did not differ substantially between both groups, neither for favorable nor for excellent outcome. Figure 2 displays mRS in the 2 matched groups (shift analysis). Mortality was lower in patients treated by MT than after bridging thrombolysis . Propensity score-based matching was slightly less efficient than multivariate matching as measured by the balance of the relevant variables between cases and controls but supported the similarity in outcome parameters (Table III in the online-only Data Supplement). Furthermore, multiple regression models (ANCOVA, logistic regression) assessing potential predictors of outcome, as well as the propensity score, confirmed the absence of an effect of the treatment choice on outcomes, such as functional independence, mortality, or NIHSS at 3 months: in all evaluated models, the P value for the treatment effect was 0.16 (Table VI in 
Discussion
Whether treatment with intravenous tPA before mechanical clot retrieval in patients with large artery anterior circulation stroke is of any benefit is currently one of the most important unanswered questions in acute stroke management. Our multivariate matched comparison of bridging therapy versus direct mechanical intervention in stroke patients with proximal vessel occlusion in the anterior circulation has 3 main findings. First, functional outcome after bridging thrombolysis is similar to outcome after direct mechanical intervention. Second, rates of sICH do not differ between the 2 groups, but rates of asymptomatic ICH are significantly higher after bridging thrombolysis than after direct mechanical intervention. Third, recanalization and reperfusion rates after bridging thrombolysis are in the same order as after direct mechanical intervention.
In the past, comparisons of bridging thrombolysis with direct mechanical intervention have been almost impossible because most patients with an acute ischemic stroke presenting within 4.5 hours after symptom onset with no contraindications received intravenous tPA. Only few months ago, after the publication of 5 positive randomized controlled trials, endovascular recanalization techniques have become an evidence-based treatment option for selected patients with stroke. [2] [3] [4] [5] [6] However, also in these trials, pretreatment with intravenous tPA was mandatory in the absence of contraindications for intravenous tPA. Indirect comparisons of bridging patients with those treated directly by mechanical intervention because of contraindications for intravenous tPA are usually limited: those treated by direct MT are presenting either late or have relevant comorbidities with a major impact on outcome, such as oral anticoagulation because of atrial fibrillation, prior subacute strokes or hemorrhages, increased bleeding risk, falls, etc.
Three previous retrospective studies compared patients treated with bridging thrombolysis with direct EVT alone and found no major differences in mortality, functional outcome, rates of sICH, and recanalization rates. [21] [22] [23] However, all 3 studies had major confounders. In the study of Kass-Hout et al 21 , bridging patients were treated significantly later than patients with direct EVT and patients in the endovascular arm could also receive tPA endovascularly, making direct comparison difficult. In the study of Leker et al 22 and Sallustio et al, 23 direct MT was only performed in patients with contraindications for intravenous tPA. Given the long-standing tradition of endovascular stroke treatment in our institution, the treating team of neurologists and neuroradiologists sometimes decided against intravenous tPA in patients with proximal vessel occlusion even though patients had no contraindications for bridging thrombolysis. Therefore, we were able to match 40 patients with no contraindications for intravenous tPA with 40 patients from the bridging cohort, which is a major strength of our analysis compared with previous studies. Clinical and radiological characteristics did not differ between the 2 groups, except for higher rates of hypercholesterolemia, coronary heart disease, and shorter intervals from symptom onset to endovascular intervention in the MT group. Shorter-time intervals from symptom onset to endovascular intervention in patients treated with direct MT compared with bridging patients have also been observed by Kass-Hout et al and in the STAR trial, 24 potentially reflecting the fact that administration of intravenous tPA before endovascular clot retrieval needs time and might even delay EVT. After matching with the multivariate approach, which resulted in better pairs concerning baseline characteristics than with the propensity score approach, functional outcome at 3 months did not differ between the 2 groups. However, mortality was lower in patients treated by direct MT than after bridging thrombolysis, without any difference in sICH but lower rates of asymptomatic ICH in the direct MT group. Therefore, direct mechanical revascularization seems to result in a similar outcome to bridging thrombolysis. Balancing risks and benefits, there is equipoise whether potential harm of intravenous tPA before MT exceeds its benefit. Given the findings of the 3 previous studies comparing bridging thrombolysis with MT and the results of our multivariate matched comparison, a future randomized controlled trial addressing this questions is justified. If direct MT in patients with acute ischemic stroke would be equally effective as bridging thrombolysis, the organization of acute stroke management would change like treatment of ST-elevation-myocardial infarction has changed a few years before. Facilitated percutaneous coronary intervention offered no benefit over primary percutaneous coronary intervention. 25, 26 Direct MT could then be the therapy of choice in stroke centers with endovascular facilities.
Our study has several limitations: this is a retrospective, nonrandomized analysis of a relatively small number of matched pairs resulting in rather large detectable differences for individual tests. Most importantly, there is a potential selection bias resulting from assignment to bridging thrombolysis or direct MT by consensus rather than randomization. Main reasons not to provide intravenous tPA to potential candidates for bridging thrombolysis were suspicion of large thrombus burden or major vessel occlusions, given the poor recanalization rates after intravenous tPA in these patients. However, given the retrospective nature of our analysis, the exact reason to withhold intravenous tPA cannot be provided for every single patient. Furthermore, we excluded patients who received intra-arterial thrombolysis in both groups, which might have biased our comparison. Starting from a rather large series (with a lost to follow-up rate of ≈6%), we carefully matched patients for variables known to influence outcome, but we cannot exclude that other unaccounted variables might have affected the treatment choice. Especially, thrombus length and collaterals are likely to have a relevant impact on outcome, but they are both not prospectively assessed in the Bernese stroke database in a standardized manner. Retrospective measurement of thrombus length is not adequately possible because of technical limitations of baseline imaging. We were therefore unable to include these factors in the matching analysis. Furthermore, matching was performed in a 1:1 and 1:2 ratio. Ideal 1:4 matching was not possible because of the limited size of the pool of potential control patients. Therefore, our results should be viewed as hypothesis generating that suggest the need of a future randomized controlled trial.
In conclusion, direct mechanical intervention may be equally effective compared with bridging thrombolysis in patients with large anterior circulation stroke. Our data suggest that there is equipoise that calls for a randomized trial. A randomized trial comparing direct MT with bridging therapy could solve this question and is currently planned.
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